Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines.
(2022) European Urology Oncology — Vol. 5, n° 2, p. 256-258 (2022)
Files
Details
- Authors
- Abstract
- (en) INTRODUCTION : International guidelines for prostate cancer (PCa) represent a valuable aid for urologists and other health care professionals engaged in the management of PCa patients. We commend the authors of international guidelines for systematically reviewing and critically analyzing a monumental amount of scientific literature, and developing evidence-based recommendations for practicing clinicians. [...]
- Affiliations
Citations
Capitanio, U., Autorino, R., Bandini, M., Briganti, A., Cheng, L., Cooperberg, M. R., Dehò, F., Gallina, A., Klotz, L., Lane, B., Montironi, R., Salonia, A., Stief, C., Tombal, B., & Montorsi, F. (2022). Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology, 5(2), 256-258. https://doi.org/10.1016/j.euo.2021.03.005 (Original work published 2022)